Morgan Stanley
KROS icon

Morgan Stanley’s Keros Therapeutics KROS Stock Holding History

Morgan Stanley’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$848K Sell
79,286
-44,826
-36% -$499K ﹤0.01% 5285
2026
Q1 		$1.37M Sell
124,112
-106,380
-46% -$1.64M ﹤0.01% 4981
2025
Q4 		$4.69M Sell
230,492
-164,611
-42% -$2.89M ﹤0.01% 4226
2025
Q3 		$6.25M Sell
395,103
-483,643
-55% -$7.15M ﹤0.01% 3964
2025
Q2 		$11.7M Sell
878,746
-818,811
-48% -$11.1M ﹤0.01% 3294
2025
Q1 		$17.3M Buy
1,697,557
+1,040,756
+158% +$12.1M ﹤0.01% 2840
2024
Q4 		$10.4M Buy
656,801
+291,504
+80% +$15.1M ﹤0.01% 3374
2024
Q3 		$21.2M Buy
365,297
+29,628
+9% +$1.46M ﹤0.01% 2745
2024
Q2 		$15.3M Buy
335,669
+46,512
+16% +$2.5M ﹤0.01% 2951
2024
Q1 		$19.1M Sell
289,157
-636,231
-69% -$37.7M ﹤0.01% 2750
2023
Q4 		$36.8M Buy
925,388
+476,687
+106% +$14.9M ﹤0.01% 2039
2023
Q3 		$14.3M Buy
448,701
+398,903
+801% +$14.9M ﹤0.01% 2789
2023
Q2 		$2M Sell
49,798
-91,172
-65% -$4M ﹤0.01% 4427
2023
Q1 		$6.02M Sell
140,970
-1,991
-1% -$101K ﹤0.01% 3621
2022
Q4 		$6.86M Buy
142,961
+81,440
+132% +$3.8M ﹤0.01% 3457
2022
Q3 		$2.31M Sell
61,521
-58,277
-49% -$2.02M ﹤0.01% 4321
2022
Q2 		$3.31M Buy
119,798
+67,970
+131% +$2.98M ﹤0.01% 4120
2022
Q1 		$2.82M Buy
51,828
+44,687
+626% +$2.29M ﹤0.01% 4250
2021
Q4 		$417K Sell
7,141
-73,071
-91% -$3.64M ﹤0.01% 5656
2021
Q3 		$3.17M Buy
80,212
+57,232
+249% +$2.04M ﹤0.01% 4169
2021
Q2 		$976K Buy
22,980
+22,693
+7,907% +$1.23M ﹤0.01% 5094
2021
Q1 		$18K Sell
287
-75,348
-100% -$4.77M ﹤0.01% 6758
2020
Q4 		$5.34M Buy
75,635
+75,008
+11,963% +$4.73M ﹤0.01% 3191
2020
Q3 		$24K Sell
627
-1,526
-71% -$60.5K ﹤0.01% 5994
2020
Q2 		$81K Buy
+2,153
New +$66.3K ﹤0.01% 5497

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley's KROS Position: Q2 2026 in Review

Morgan Stanley reduced its Keros Therapeutics (KROS) stake by 36% in Q2 2026, selling an estimated $499K and leaving 79,286 shares worth $848K. The position accounts for ﹤0.01% of the portfolio, ranked #5285.

Morgan Stanley first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $36.8M in Q4 2023. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Morgan Stanley held 79,286 shares of Keros Therapeutics worth $848K as of Q2 2026.
  • Morgan Stanley sold 44,826 Keros Therapeutics shares in Q2 2026, an estimated $499K.
  • Keros Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5285 holding.
  • Morgan Stanley first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Keros Therapeutics position peaked at $36.8M in Q4 2023.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.